A Spotlight on Drug-Induced Vasculitis.
Cocaine
Drug-induced ANCA-associated vasculitis
Drug-induced vasculitis (DIV)
Granulocyte colony-stimulating factor (G-CSF)
Hydralazine
Immune checkpoint inhibitors (ICIs)
Minocycline
Propylthiouracil
Tumor necrosis factor-α (TNF-α)
Journal
Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
16
08
2022
pubmed:
22
9
2022
medline:
12
10
2022
entrez:
21
9
2022
Statut:
ppublish
Résumé
Drug-induced vasculitis (DIV) is a rare form of vasculitis related to the use of various drugs. DIV primarily affects small to medium size vessels, but it can potentially involve vessels of any size. Differentiating between primary systemic vasculitis and DIV can be challenging; however, it is crucial, so that the offending agent can be discontinued promptly. The clinical phenotype of DIV is protean and depends on the size of the affected vessels. It ranges from arthralgias, to an isolated cutaneous rash, to severe single or multi-organ involvement. While withdrawal of the offending drug is the most important step in management, a significant number of patients require immunosuppressive therapy for varying periods of time. DIV can affect any vascular bed size, leading to protean vasculitic syndromes. Increased awareness among general practitioners, specialty, and subspecialty physicians is crucial for early recognition, and withdrawal of drug for better outcomes.
Identifiants
pubmed: 36129631
doi: 10.1007/s11926-022-01088-0
pii: 10.1007/s11926-022-01088-0
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-336Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.